autologous tumor infiltrating lymphocytes
Cell therapyexperimental
Clinical trial activity
97 trials · 65 clinical orgs · 0 marketing orgs
Phase 1
71
Phase 2
40
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2009 (NCT00863330)
Timeline
Indications
Studied for
- Adenocarcinoma · Phase 1
- Adenocarcinoma of Lung · Phase 1
- Adult · Early Phase 1
- Biliary Tract Neoplasms · Phase 2
- Brain Neoplasms · Phase 1/Phase 2
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Adenosquamous · Phase 1
- Carcinoma, Giant Cell · Phase 2
- Carcinoma, Hepatocellular · Phase 1/Phase 2
- Carcinoma, Merkel Cell · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Squamous Cell · Phase 1
- Carcinoma, Transitional Cell · Phase 2
- Central Nervous System Neoplasms · Phase 1
- Cholangiocarcinoma · Phase 2
- Chondrosarcoma · Phase 2
- Colonic Neoplasms · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 2
- DNA Mismatch Repair · Phase 2
- Drug Evaluation · Phase 1
- Drug-Related Side Effects and Adverse Reactions · Phase 1/Phase 2
- Drugs, Investigational · Phase 1
- Drug Therapy · Early Phase 1
- Esophageal Neoplasms · Phase 1/Phase 2
- Fallopian Tube Neoplasms · Phase 1/Phase 2
- Gallbladder Neoplasms · Phase 1/Phase 2
- Gastrointestinal Neoplasms · Phase 1/Phase 2
- Genital Neoplasms, Female · Phase 1
- Giant Cell Tumor of Bone · Phase 2
- Glioblastoma · Phase 1/Phase 2
- Glioma · Phase 1/Phase 2
- Hamartoma · Phase 1/Phase 2
- Immunotherapy · Phase 1
- Intestinal Neoplasms · Phase 1/Phase 2
- Liver Neoplasms · Phase 1
- Lung Neoplasms · Phase 2
- Lymphocytes, Tumor-Infiltrating · Phase 1/Phase 2
- Melanoma · Phase 2
- Meningioma · Phase 1/Phase 2
- Mesothelioma · Phase 2
- Microsatellite Instability · Phase 2
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 2
- Neoplasms, Squamous Cell · Phase 2
- Neuroendocrine Tumors · Phase 2
- Osteosarcoma · Phase 2
- Ovarian Diseases · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Rectal Neoplasms · Phase 1/Phase 2
- Rhabdomyosarcoma · Phase 1
- Safety · Phase 1
- Sarcoma · Phase 2
- Sarcoma, Ewing · Phase 1
- Small Cell Lung Carcinoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 2
- Thyroid Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 2
- Urogenital Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 2
- Uveal Neoplasms · Phase 2
Mechanism of action
- Tumor antigensImmunity, passive
Tumor antigens immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous tumor infiltrating lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07183852 | Phase 1 | Mar 31, 2026 | Vastra Gotaland Region |
| NCT07288073 | Phase 2 | Jan 31, 2026 | Harvard University, Iovance |
| NCT07310784 | Phase 2 | Dec 16, 2025 | Government of China |
| NCT07028008 | N/A | Oct 15, 2025 | Sungkyunkwan University |
| NCT07105176 | Phase 1 | Aug 30, 2025 | Qingdao Sino-Cell Biomedicine Co.,Ltd. |
| NCT07106814 | Early Phase 1 (Phase 1) | Aug 29, 2025 | Anhui Medical University, Leman Biotech Co., Ltd |
| NCT06941818 | Phase 1 | Jul 10, 2025 | Peking University, Qingdao Sino-Cell Biomedicine Co.,Ltd. |
| NCT06961786 | Phase 1 | Jun 25, 2025 | TILT Biotherapeutics Ltd., University of Copenhagen |
| NCT07035002 | Phase 1 | Dec 31, 2024 | Jiao Tong University |
| NCT06783270 | Phase 1 | Dec 16, 2024 | University of Copenhagen |
| NCT06613152 | Early Phase 1 (Phase 1) | Oct 31, 2024 | Qingdao Sino-Cell Biomedicine Co.,Ltd., Qingdao University |
| NCT06640582 | Phase 1/Phase 2 (Phase 2) | Oct 20, 2024 | Essen Biotech |
| NCT06530303 | Phase 1/Phase 2 (Phase 2) | Sep 29, 2024 | Essen Biotech |
| NCT06532799 | Phase 1/Phase 2 (Phase 2) | Sep 10, 2024 | Essen Biotech |
| NCT06473961 | Phase 1 | Sep 1, 2024 | Government of China |
| NCT06532812 | Phase 1/Phase 2 (Phase 2) | Aug 22, 2024 | Essen Biotech |
| NCT06538012 | Phase 1/Phase 2 (Phase 2) | Aug 20, 2024 | Essen Biotech |
| NCT06455917 | Phase 2 | Jul 31, 2024 | University of Basel |
| NCT06491225 | Phase 1 | Jul 18, 2024 | Grit Biotechnology |
| NCT06453057 | N/A | Jul 4, 2024 | Grit Biotechnology |
Showing 20 of 97 trials
Page 1 / 5
Organizations
Research & Development (65)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Iovance | For profit | 13 | 7 | 2 | 2015 |
| Government of China | Government | 11 | 10 | 2 | 2021 |
| Huazhong University of Science and Technology | Academic/Hospital | 9 | 2 | 2 | 2018 |
| Grit Biotechnology | For profit | 7 | 7 | 2 | 2021 |
| Shanghai Gencells Therapeutics Co., Ltd. | For profit | 7 | 6 | 1 | 2021 |
| Qingdao Sino-Cell Biomedicine Co.,Ltd. | For profit | 6 | 4 | 1 | 2022 |
| University of Copenhagen | Academic/Hospital | 6 | 4 | 2 | 2017 |
| Essen Biotech | For profit | 5 | 5 | 1 | 2024 |
| Bristol-Myers Squibb | For profit | 4 | 0 | 2 | 2017 |
| University of South Florida | Academic/Hospital | 4 | 4 | 2 | 2017 |
| Fudan University | Academic/Hospital | 3 | 3 | 1 | 2017 |
| Jiao Tong University | Academic/Hospital | 3 | 1 | 1 | 2020 |
| Jinlin University | Academic/Hospital | 3 | 1 | 1 | 2021 |
| Qingdao University | Academic/Hospital | 3 | 2 | 1 | 2022 |
| Sun Yat-Sen University | Academic/Hospital | 3 | 2 | 1 | 2019 |
| University of Basel | Academic/Hospital | 3 | 3 | 2 | 2020 |
| University of Lausanne | Academic/Hospital | 3 | 3 | 1 | 2018 |
| University of Pittsburgh | Academic/Hospital | 3 | 3 | 1 | 2018 |
| Vastra Gotaland Region | Government | 3 | 3 | 1 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 1 | 2023 |
65 organizations
Page 1 / 4